Delayed IPF Diagnosis Negatively Impacts Patients by Delaying Treatment According to Global Survey of Pulmonologists1
8.10.2015 07:36 | Business Wire
A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis (IPF) negatively impacts patients. 79% stated that delayed diagnosis will delay initiating treatment that slows disease progression.1
IPF is a progressive and life threatening lung disease.2 Diagnosis of IPF is challenging, requiring a series of specific diagnostic tests with the median time from first symptoms to diagnosis between one and two years.2,3,4 Initial misdiagnosis occurs in around half of patients because symptoms are similar to other respiratory diseases like chronic obstructive pulmonary disease (COPD), asthma and congestive heart failure.4 However over 80% of patients with IPF have a distinctive, Velcro-like crackling sound that can be detected through a stethoscope.5
The survey showed that slowing disease progression is considered the biggest benefit of initiating treatment when IPF is first diagnosed (81%) and pulmonologist’s primary reason for selecting a pharmaceutical treatment for IPF (78%). Improving patient quality of life was the second highest motivation for pulmonologists when selecting an IPF treatment (63%).1
In addition to asking pulmonologists about their approaches to treatment, the survey asked participants to consider IPF from the patient’s perspective, including impact of the disease. When asked what was most important for an IPF patient to understand in terms of knowing how IPF will affect them, 77% of pulmonologists stated ‘knowing what treatment options are available for IPF’, and 68% said ‘knowing that IPF is unpredictable and that their condition could change suddenly and unexpectedly’.
Top of mind for physicians when thinking about the impact of IPF were breathlessness (54%), lung function (21%) and exacerbations (13%).1 As IPF progresses lung function gradually and irreversibly declines leading to difficulty breathing and decreased oxygen supply to the major body organs.6 Exacerbations – events of acute respiratory worsening – are a risk to all IPF patients and they can occur at any time during the course of the disease without warning or known cause.7 Acute exacerbations can impact the course of the disease, often leading to death within a few months, making them a crucial treatment consideration for pulmonologists managing IPF patients.8
“As someone who talks every day to people with IPF, it is fascinating to see how pulmonologists view and prioritise the impact of the disease on patients and make treatment decisions,” said Dagmar Kauschka, Chairperson of the German patient advocacy group Lungenfibrose e.V.. “We put a lot of time and energy into supporting IPF patients over their day-to-day concerns such as breathlessness and the risk of exacerbations. One of our goals is to fight for patient support as a regular part of therapy. We are reassured to see through this survey that pulmonologists do recognise the key concerns when thinking about the impact of IPF on their patients.”
~ ENDS ~
Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/08_oktober_2015_ipf.html
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
Media + PR
Dr Kristin Jakobs
Phone: +49 6132 77 144553
Fax: +49 6132 – 77 6601
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Altierre Strengthens Executive Team in Europe With Hiring of Guillaume Vicot and Niclas Qvist22.8.2017 12:00 | Pressemelding
Altierre Corp., a provider of the world’s highest density, ultra-low energy, long-range wireless technology and applications for the Internet of Things (IoT) market, today announced two additions to its France-based European executive team. Guillaume Vicot has joined the company as General manager, Europe, Middle East and Asia (EMEA) and Niclas Qvist has joined as Vice President, Partner management & Marketing. Vicot joins Altierre’s management team after 17 successful years in the Auto-ID industry, barcode scanning and mobile computing. He most recently served as Vice President of sales, Western Europe, for PSC / Datalogic, leader in the bar code scanning industry, where he oversaw a team of more than 100 people and developed a tactical go-to-market strategy, achieving revenue well over US$100 million. “Guillaume has many top level strategic relationships with retailers
IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 20:11 | Pressemelding
Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25 | Pressemelding
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the
IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00 | Pressemelding
IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman
PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03 | Pressemelding
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom